Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC).
Dual recognition from G2 validates Zilliz's breakthrough approach to delivering enterprise-grade performance without operational complexity.
SAN FRANCISCO, July 11, 2025 /PRNewswire/ -- Zilliz, the company behind...
Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation...
"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...
"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential approval
The Viral Vectors and Plasmid DNA Manufacturing Market forecast indicates a surge past $6 billion by 2025, driven by gene therapy advancements. The report highlights market dynamics, growth prospects, and regulatory challenges impacting this sector. Discover innovative opportunities and key players in this evolving landscape.
The Viral Vectors and Plasmid DNA Manufacturing Market forecast indicates a surge past $6 billion by 2025, driven by gene therapy advancements. The report highlights market dynamics, growth prospects, and regulatory challenges impacting this sector. Discover innovative opportunities and key players in this evolving landscape.